TMCITreace Medical Concepts shows potential for growth driven by its innovative bunion correction system, but faces profitability challenges and a volatile technical outlook. Investors should monitor upcoming earnings and market sentiment.
Treace Medical Concepts operates in the growing medical technology sector, focusing on orthopedic solutions. While its specialized products address specific medical needs, broader thematic tailwinds are not as pronounced as in other tech sectors.
Treace Medical Concepts exhibits revenue growth, but is currently unprofitable and faces significant operating expenses. Its balance sheet shows manageable debt but declining cash reserves over recent years.
The stock is trading below key moving averages, indicating a bearish short-to-medium term trend, though some oscillators suggest a potential for a bounce. Support levels need to be monitored.
| Factor | Score |
|---|---|
| Aging Population & Healthcare Demand | 75 |
| Medical Device Innovation | 80 |
| Regulatory Landscape (Medical Devices) | 50 |
| Competition in Orthopedics | 60 |
| Shift to Minimally Invasive Procedures | 70 |
| Factor | Score |
|---|---|
| Valuation | 60 |
| Profitability | 20 |
| Growth | 70 |
| Balance Sheet Health | 65 |
| Cash Flow | 30 |
| Factor | Score |
|---|---|
| Trend Analysis | 30 |
| Momentum | 50 |
| Volume Confirmation | 60 |
| Support & Resistance | 75 |
| MACD | 40 |
Positive Cash Flow from Operations
The company has a positive operating cash flow of $4.198 million in Q1 2025, indicating its core business operations are generating cash.
Improving EPS Quarter-over-Quarter
EPS has improved from -0.36 in Q1 2024 to -0.30 in Q2 2025, showing a positive trend in earnings.
Consistent Net Losses
The company has reported net losses for all analyzed periods, with net income in 2024Q4 being -$0.501 million and a TTM net income of -$31.783 million.
Significant Debt Load
The company has a total debt of $69.653 million in 2024Q4 and total liabilities of $104.202 million, with a negative EPS of -$0.85 TTM.
August 2025
6
Next Earnings Date
H: $-0.26
A: $-0.29
L: $-0.31
H: 47.14M
A: 47.08M
L: 47.00M
Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to correct three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion. It also provides Lapiplasty mini-incision system designed to allow the Lapiplasty procedure to be performed through a 3.5cm incision. In addition, the company offers Adductoplasty system designed for reproducible correction of metatarsus adductus deformities and osteoarthritis of the midfoot. It serves physicians, surgeons, ambulatory surgery centers and hospitals related to the surgical management of bunion and related midfoot deformities. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.
10.02 USD
The 39 analysts offering 1 year price forecasts for TMCI have a max estimate of 14.50 and a min estimate of 8.00.